The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | The Phase I/II prospective EORTC study: updating quality of life assessment in multiple myeloma
Charalampia Kyriakou, MD, PhD, University College London Hospitals NHS Trust (UCLH), London, UK, discusses the Phase I/II prospective EORTC study, which aimed to update the EORTC quality of life multiple myeloma module (EORTC QLQ-MY20). Dr Kyriakou highlights the need to update quality of life assessment to capture the real issues affecting patients with the latest treatments. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Obviously, in myeloma we witness major advances in therapies and it’s quite important because it’s excellent that we have managed to prolong the survival of our patients and it’s extremely important to make sure that we look into the patient’s quality of life. The measures we have in assessing the quality of life of patients were developed more than 20 years ago. So with the EORTC we had this prospective study to try to update the quality of life questionnaire, the Myeloma 20, to make sure that with the new treatments we can really address the real issues that bother patients, the real quality of life issues that affect patients nowadays with the new therapies as well...
Obviously, in myeloma we witness major advances in therapies and it’s quite important because it’s excellent that we have managed to prolong the survival of our patients and it’s extremely important to make sure that we look into the patient’s quality of life. The measures we have in assessing the quality of life of patients were developed more than 20 years ago. So with the EORTC we had this prospective study to try to update the quality of life questionnaire, the Myeloma 20, to make sure that with the new treatments we can really address the real issues that bother patients, the real quality of life issues that affect patients nowadays with the new therapies as well. And what we have seen in this early stage phase is Phase I and II. We conducted an earlier literature review and then we addressed framework interviews to patients and healthcare professionals, experts in myeloma. and based on the feedback and the issues that came up as very significant from this work, we have now developed a new proposed questionnaire that will replace the Myeloma 20 and hopefully this one will have broader coverage of the updated therapy, real issues that are impacting on our patients’ quality of life.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
